Premium
Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy
Author(s) -
Sogani Pramod C.,
Vagaiwala Minoo R.,
Whitmore Willet F.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(1984)54:4<744::aid-cncr2820540426>3.0.co;2-p
Subject(s) - flutamide , medicine , antiandrogen , endocrine system , urology , cancer , oncology , prostate cancer , carcinoma , hormone , androgen receptor
Seventy‐two patients with advanced prostatic carcinoma without previous endocrine therapy were treated with an oral nonsteroidal antiandrogen, flutamide. Sixty‐three patients (87.5%) had a favorable response, and 9 patients showed no response. Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy.